GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new ...
With the acceleration of global industrialization and urbanization, air pollution has become an escalating environmental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results